Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany

被引:3
作者
Szejko, Natalia
Becher, Eva [2 ]
Heimann, Florian [3 ]
Grotenhermen, Franjo
Mueller-Vahl, Kirsten R. [1 ]
机构
[1] Hannover Med Sch, Clin Psychiat Social Psychiat & Psychotherapy, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Univ Bielefeld, Dept Sex & Gender spec Med, Bielefeld, Germany
[3] Cannabis Apotheke de, Apotheke LUX99, Hurth, Germany
关键词
medicinal cannabis; tetrahydrocannabinol; cannabidiol; patients' experience; side effects;
D O I
10.1055/a-2261-2269
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Up to now, it is unclear whether different medicinal cannabis (MC) strains are differently efficacious across different medical conditions. In this study, the effectiveness of different MC strains was compared depending on the disease to be treated. Methods This was an online survey conducted in Germany between June 2020 and August 2020. Patients were allowed to participate only if they received a cannabis -based treatment from pharmacies in the form of cannabis flowers prescribed by a physician. Results The survey was completed by n=1,028 participants. Most participants (58%) have used MC for more than 1 year, on average, 5.9 different strains. Bedrocan (pure tetrahydrocannabinol to pure cannabidiol [THC:CBD]=22:<1) was the most frequently prescribed strain, followed by Bakerstreet (THC:CBD=19:<1) and Pedanios 22/1 (THC:CBD=22:1). The most frequent conditions MC was prescribed for were different pain disorders, psychiatric and neurological diseases, and gastrointestinal symptoms. Overall, the mean patient-reported effectiveness was 80.1% (range, 0-100%). A regression model revealed no association between the patient-reported effectiveness and the variety. Furthermore, no influence of the disease on the choice of the MC strain was detected. On average, 2.1 side effects were reported (most commonly dry mouth (19.5%), increased appetite (17.1%), and tiredness (13.0%)). However, 29% of participants did not report any side effects. Only 398 participants (38.7%) indicated that costs for MC were covered by their health insurance. Conclusions Patients self-reported very good efficacy and tolerability of MC. There was no evidence suggesting that specific MC strains are superior depending on the disease to be treated.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 27 条
  • [1] Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly
    Abuhasira, Ran
    Schleider, Lihi Bar-Lev
    Mechoulam, Raphael
    Novack, Victor
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 49 : 44 - 50
  • [2] Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study
    Bar-Lev Schleider, Lihi
    Mechoulam, Raphael
    Sikorin, Inbal
    Naftali, Timna
    Novack, Victor
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [3] Baron E P., PATTERNS MED CANNABI, DOI [10.1186/s10194-018-0862-2, DOI 10.1186/S10194-018-0862-2]
  • [4] Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users
    Belendiuk, Katherine A.
    Babson, Kimberly A.
    Vandrey, Ryan
    Bonn-Miller, Marcel O.
    [J]. ADDICTIVE BEHAVIORS, 2015, 50 : 178 - 181
  • [5] Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain
    Boehnke, Kevin F.
    Scott, J. Ryan
    Litinas, Evangelos
    Sisley, Suzanne
    Clauw, Daniel J.
    Goesling, Jenna
    Williams, David A.
    [J]. JOURNAL OF PAIN, 2019, 20 (11) : 1362 - 1372
  • [6] Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry
    Brown, Joshua D.
    Costales, Brianna
    van Boemmel-Wegmann, Sascha
    Goodin, Amie J.
    Segal, Richard
    Winterstein, Almut G.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [7] Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis
    Brunt, Tibor M.
    van Genugten, Marianne
    Honer-Snoeken, Kathrin
    van de Velde, Marco J.
    Niesink, Raymond J. M.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (03) : 344 - 349
  • [8] Cannabis use in Attention-Deficit/Hyperactivity Disorder (ADHD): A scoping review
    Francisco, Ana Paula
    Lethbridge, Grace
    Patterson, Beth
    Bergmann, Carolina Goldman
    Van Ameringen, Michael
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2023, 157 : 239 - 256
  • [9] Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis
    Kosiba, Jesse D.
    Maisto, Stephen A.
    Ditre, Joseph W.
    [J]. SOCIAL SCIENCE & MEDICINE, 2019, 233 : 181 - 192
  • [10] Kuhathasan N., 2021, J MED INTERNET RES, V14, P23